Previous 10 | Next 10 |
Webcast Scheduled for Wednesday, March 1, 2023, at 4:30 p.m. Eastern SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL ), a contract development and manufacturing organization (CDM...
Expansion in Scope of Projects Seen Across All CDMO Service Capabilities and Manufacturing Facilities; Addressing Evolving Customer Needs Through Customized Project Modifications Existing Customer Wins Supplement Continued Momentum in Growing Business through Signing of New Customers ...
SAN DIEGO and GAINESVILLE, Ga., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule th...
With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers’ Goal of Delivering Impactful Medicines to Society New Ticker (NASDAQ: SCTL) to Initiate Trading on March 22, 2022 SAN DIEGO...
Recro Pharma, Inc. (REPH) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Stephanie Diaz - IR David Enloe - President & CEO Ryan Lake - CFO Conference Call Participants Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Capital Christine Rains - William Bla...
The following slide deck was published by Recro Pharma, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Recro Pharma, Inc. 2021 Q4 - Results - Earnings Call Presentation
Recro Pharma press release (NASDAQ:REPH): Q4 GAAP EPS of $0.04 beats by $0.11. Revenue of $22.3M (+125.0% Y/Y) beats by $0.89M. For further details see: Recro Pharma GAAP EPS of $0.04 beats by $0.11, revenue of $22.3M beats by $0.89M
Recro Pharma press release (NASDAQ:REPH): Q4 GAAP EPS of -$0.04 beats by $0.03. Revenue of $22.3M (+125.0% Y/Y) beats by $0.89M. For further details see: Recro Pharma GAAP EPS of -$0.04 beats by $0.03, revenue of $22.3M beats by $0.89M
Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew by 147% Including IriSys Acquisition Company to Host Conference Ca...
SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small mole...
News, Short Squeeze, Breakout and More Instantly...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATE...
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. ...
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approxi...